Researchers at Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, contributed abstracts and participated in presentations at the 2024 ASCO Annual Meeting in Chicago, May 31-June 3.
The ASCO (American Society of Clinical Oncology) Annual Meeting is pivotal for advancing cancer research because it serves as a premier platform for oncologists, researchers and health care professionals to share groundbreaking research, treatments and emerging clinical practices. This convergence of experts fosters collaboration and helps accelerate the translation of research findings into clinical applications.
Read on to find out who contributed to abstracts this year and to learn about some of the latest studies.
Clinical Science Symposium (Oral Presentation)
Head and Neck Cancer
Abstract 6009: Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group | Bryan Bell, M.D., D.D.S., FACS, et al.
Rapid Oral Abstract Session
Lung Cancer
Abstract 8521: Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001) | Rachel Sanborn, M.D., et al.
Melanoma/Skin Cancer
Abstract LBA9512: Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial | Matthew Taylor, M.D., et al.
Oral Abstract Session
Lung Cancer—Non-Small Cell Metastatic
Abstract LBA8505: Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial. | Rachel Sanborn, et al.
Symptom Science and Palliative Care
Abstract 12008: Walking dose required to achieve a clinically meaningful reduction in cancer-related fatigue among patients with breast cancer receiving chemotherapy: A URCC NCORP nationwide prospective cohort study | Alison Conlin, M.D., et al.
Poster Sessions
Lung Cancer
Abstract 8090: Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC) | Rachel Sanborn, M.D., et al.
Abstract TPS8118: A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC | Rachel Sanborn, M.D., et al.
Abstract TOS8650: AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors | Rom Leidner, M.D., et al.
Abstract 8556: A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors | Matthew Taylor, M.D., et al.
Gastrointestinal Cancer—Colorectal and Anal
Abstract 3556: Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites | Rachel Sanborn, M.D., et al.
Symptom Science and Palliative Care
Abstract 12141: Pilot evaluation of portable scalp cooling for chemotherapy-associated alopecia in early-stage breast cancer | David Page, M.D., Alison Conlin, M.D., et al.
Developmental Therapeutics—Immunotherapy
Abstract TPS2689: A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors | Brendan Curti, M.D., et al.
Abstract 2615: A phase 2a safety run-in and preliminary efficacy study of liposomal gemcitabine (FF-10832) in combination with pembrolizumab in patients with advanced solid tumors | Brendan Curti, M.D., et al.
Abstract: 2623: A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab | Brendan Curti, M.D., et al.
Abstract 2542: Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors | Rom Leidner, M.D., et al.
Abstract TPS2677: An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT‑112 in human leukocyte antigen-C*08:02–positive adult patients with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation | Rom Leidner, M.D., et al.
Abstract 2602: Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors | Matthew Taylor, M.D., et al.
Publication Only
Care Delivery and Quality Care
Abstract e13811: MRI-Linac radiation therapy outcomes in patients with prostate, breast and other advanced malignancies | Marka Crittendon, Ph.D., Kristina Young, M.D., Ph.D., et al.
Abstract e23109: CGP-based IO biomarker assessment and treatment utilization across a major US health system | Carlo Bifulco, Ph.D., Brian Piening, Ph.D., et al.
Providence center of excellence for precision immuno-oncology and cellular therapy
Since 1993, cancer research has been the primary focus of the Earle A. Chiles Research Institute, the research arm of Providence Cancer Institute of Oregon. Under the leadership of Walter J. Urba, M.D., Ph.D., our team of physicians and scientists work together to improve cancer treatment methods – seamlessly joining lab research and clinical trials with patient care.
Our main area of research is cancer immunotherapy, and with the advancements in genomic sequencing we bring together the power of immunotherapy and personalized medicine to accelerate leading-edge research and groundbreaking discoveries for patients with cancer.
To learn more about Earle A. Chiles Research Institute:
- Visit our website.
- Follow us on X, LinkedIn and Facebook.
- Read our blog for the latest news and announcements.
Related news
Celebrating World Immunology Day
New vaccine being studied for HPV+ head and neck cancer
How promoting apoptosis in new study may help people with cancer
